Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Study Shows Antibiotics Effective for Treatment of Small Skin Infections

By Vanderbilt University Medical Center | June 30, 2017

New multicenter research, which included Vanderbilt University Medical Center investigators, could change treatment approaches to simple skin abscesses, infections often caused by Staphylococcus aureus (staph) bacteria.

The study, published in the New England Journal of Medicine, shows that adults and children who have simple abscesses five centimeters or smaller in diameter have higher cure rates if the abscess is drained in combination with antibiotic treatment, either trimethoprim-sulfamethoxazole (TMP/SMX or Bactrim) or clindamycin, compared to drainage alone.

“We drained the abscess, measured it carefully to make sure it was less than five centimeters and then we randomized participants to receive a placebo or one of the antibiotics — clindamycin or TMP/SMX. What we saw is that in fact antibiotics are helpful. You are more likely to get better if you have antibiotics on board than if you don’t. And we also saw in children that clindamycin was associated with fewer recurrences in the one month of follow up,” said Buddy Creech, M.D., MPH, associate professor of Pediatric Infectious Diseases and director of the Vanderbilt Vaccine Research Program (VVRP).

Staph, including methicillin-resistant S. aureus (MRSA) strains, causes most skin and soft tissue infections, but the appropriate strategy for the treatment of these infections has not been defined. Clindamycin and TMP/SMX are often recommended for outpatient treatment of abscesses because of their low cost and their ability to fight community-acquired MRSA strains, but data on efficacy and safety have been limited, prompting the current study.

Researchers enrolled 786 participants at six sites, including Vanderbilt; University of Chicago Medical Center; San Francisco General Hospital; Harbor-University of California, Los Angeles, Medical Center; Washington University, St. Louis; and Morehouse School of Medicine-Emory University.

Of the participants, 505 were adults and 281 were children. Bacteria isolated from the abscesses included 527 samples identified as staph and 388 samples identified as methicillin-resistant S. aureus (MRSA). Patients were randomized to receive either a placebo, clindamycin, or TMP/SMX for 10 days after the drainage of the abscess.

Researchers found that clindamycin and TMP/SMX were equally effective in adults, while clindamycin in children had a slightly higher cure rate in children and more frequently prevented recurrence of infection. Clindamycin had an overall cure rate of about 83 percent of participants; TMP/SMX about 82 percent; and the placebo about 70 percent.

Creech noted that it’s important for physicians to culture the fluid from drained abscesses so that infectious disease experts can track strains throughout the community and treat with appropriate antibiotics. In the case of this study, some participants had a clindamycin-resistant staph, rendering that antibiotic ineffective.

“Because antibiotics only work if the germ is susceptible to that antibiotic we really need to know the types of strains that are circulating in a community — not just for the individual patient but public health in general,” Creech said.


Filed Under: Drug Discovery

 

Related Articles Read More >

TransCelerate CEO Janice Chang wants trials to become part of routine care
STEERLife’s FragMelt platform manufactures drugs with heat sensitive active ingredient 
S&P report highlights Big Pharma’s concentration risk amid pre-JPM deal flurry
Eli Lilly in the Drug Discovery & Development Pharma 50
Lilly Phase 3b trial shows roughly 40-fold higher combined arthritis and weight-loss response
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2026 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE